Previous Research Funding
- “MICA Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) study”, CI Prof. Julian Marchesi (Imperial College London), MRC DPFS MR/X004996/1; 01/09/2022-28/02/2027. £1,728,017.
- “Development of recombinant surfactant protein D therapy to prevent neonatal chronic lung disease”, CI Prof. Howard Clark (Southampton/UCL); MRC (MR/P026907/1; 2019-2021). £2,765,801.
- “Investigating the therapeutic potential of biomarker targeted MSCTRAIL in malignant pleural mesothelioma”, CI Prof. Sam Janes (UCL); Innovate UK (105196; 2019-2021). £638,609.
- “Phase I/II clinical trials evaluating AAV-mediated gene therapy for a severe paediatric metabolic liver disease: Ornithine Transcarbamylase deficiency”, CI Prof. Paul Gissen (UCL); MRC DPFS (MR/S019111/1; 2019-2023). £3,920,211.
- “A Practical Adaptive and Novel Designs Toolkit (PANDA)”, CI Dr. Munya Dimairo (University of Sheffield); NIHR CTU Support Funding Opportunity (R/157221; 2019-2021). £98,886.
- “Phase I study of transfer of effector memory T cells (Tem) following allogenic stem cell transplantation”, CI Prof. Ronjon Chakraverty (UCL); MRC DPFS (MR/R025436/1; 2018-2023). £1,040,481.
- “Development of user-friendly web-based software for conducting Bayesian Phase I dose-escalation studies”, CI Dr Lisa Hampson (Lancaster University); MRC Hub for Trials Methodology Research (Project N78; 2016-2018). £35,477.
Previous Research Supervision
- 2020 - 2021: A. Uda, MPH, Imperial College London
- 2019 - 2020: D. Devassy, MSc Clinical Trials, UCL
- 2016 - 2017: A. Florou, MSc Clinical Trials, UCL